http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101589135-B1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 |
filingDate | 2011-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2016-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2016-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-101589135-B1 |
titleOfInvention | Humanized anti-EMAPII antibodies and uses thereof |
abstract | The present invention provides a humanized anti-EMAPII antibody, the use of said humanized antibody, and diagnostic and pharmaceutical compositions containing said humanized antibody. The anti-EMAPII humanized antibody of the present invention exhibits reduced immunogenicity, increased half-life, etc. while having equivalent or improved antigen binding ability as compared to the parent monoclonal antibody. Therefore, the humanized anti-EMPII antibody of the present invention can be used more effectively as a diagnostic agent for EMAPII and as a therapeutic agent for diseases mediated by EMAPII. |
priorityDate | 2011-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1391.